Is Your Software a Medical Device? FDA Issues Six Digital Health Guidance Documents

McDermott Will & Emery
Contact

McDermott Will & Emery

The FDA recently released six guidance documents as part of the agency’s continued focus on updating the regulatory stance on software as a medical device and other digital health products. The updated guidance documents reflect the need for a more flexible, risk-based approach to regulation that accommodates a rapidly evolving technological landscape. This On the Subject summarizes the key provisions and changes presented in the guidance, and discusses next steps for stakeholders impacted by FDA’s evolving approach to digital health regulation.

IN DEPTH


The 21st Century Cures Act, enacted in December 2016, amended the definition of “medical device” in section 201(h) of the Federal Food, Drug, and Cosmetic Act (FDCA) to exclude five distinct categories of software or digital health products. In response, the US Food and Drug Administration (FDA) issued new digital health guidance and revised several pre-existing medical device guidance documents. FDA also stated that it would continue to assess how to update and revise these guidance documents as its thinking evolved.

Late last week, FDA issued five final guidance documents and re-issued a draft guidance document to better reflect FDA’s current thinking on software as a medical device (SaMD) and other digital health products:

· Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act – Guidance for Industry and Food and Drug Administration Staff

· General Wellness: Policy for Low Risk Devices – Guidance for Industry and Food and Drug Administration Staff

· Policy for Device Software Functions and Mobile Medical Applications – Guidance for Industry and Food and Drug Administration Staff

· Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices – Guidance for Industry and Food and Drug Administration Staff

· Off-The-Shelf Software Use in Medical Devices – Guidance for Industry and Food and Drug Administration Staff

· Clinical Decision Support Software – Draft Guidance for Industry and Food and Drug Administration Staff

Most of the guidance documents reflect modest changes to prior draft guidance documents that describe categories of low-risk health and wellness devices that FDA does not intend to regulate. FDA’s new draft Clinical Decision Support (CDS) Software guidance, however, provides a new and more detailed analysis of risk factors that FDA will apply to determine whether a CDS tool is a medical device. FDA updated its previously issued draft CDS guidance without finalizing it. Although the new guidance does not explain why FDA is reissuing the CDS guidance in draft, the new draft guidance seems to reflect the agency’s attempt to better align its definition of non-device software with the often misunderstood and misinterpreted statutory definition of CDS in section 520(o)(1)(E) of the Cures Act. The chart below summarizes the key provisions and changes to these guidance documents.

Digital health products can present a particular challenge for developers and regulators in assessing the appropriate regulatory pathways for a new product. The updated guidance documents reflect the need for a more flexible, risk-based approach to regulation that accommodates a rapidly evolving technological landscape. These documents also reflect what appears to be the new normal for digital health regulation—the need for iterative thinking and ongoing revisions to interpretive guidance documents to keep pace with a constantly changing marketplace.

Guidance: Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act – Guidance for Industry and Food and Drug Administration Staff

Overview
FDA finalized its draft guidance, which provides FDA’s current thinking regarding the amended definition of a “device” and the resulting impact it has on FDA guidance documents related to medical device software that predate the Cures Act. The guidance describes changes to the following four guidance documents at a high level:

  1. General Wellness: Policy for Low Risk Devices – Guidance for Industry and Food and Drug Administration Staff
  2. Policy for Device Software Functions and Mobile Medical Applications – Guidance for Industry and Food and Drug Administration Staff
  3. Off-the-Shelf Software Uses in Medical Devices
  4. Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices – Guidance for Industry and Food and Drug Administration Staff

FDA clarified that hardware with general wellness intended uses that relate to maintaining or encouraging a general state of health or healthy activity that otherwise meet the definition of a “device” under section 201 of the FDCA will continue to be regulated as devices.

FDA also withdrew its Guidance for the Submission of Premarket Notifications for Medical Image Management Devices, because some software functions described therein no longer meet the definition of a “device.” For the Medical Image Management Devices that continue to meet the definition of “device,” FDA acknowledged that the guidance was out-of-date and encouraged medical device manufacturers to reference the FDA-recognized versions of voluntary consensus standards instead.

Guidance: General Wellness: Policy for Low Risk Devices – Guidance for Industry and Food and Drug Administration Staff

Overview
FDA previously finalized its draft guidance on General Wellness Products in 2016 (previously discussed here).

FDA clarified that software functions that are intended for maintaining or encouraging a healthy lifestyle and are unrelated to the diagnosis, cure, mitigation, prevention or treatment of a disease or condition are excluded from the definition of “device.”

The title of Section V has been changed to “Examples of General Wellness Products that Are Not Medical Devices and Examples of General Wellness Products that Are Medical Devices for which FDA Does Not Intend to Enforce Requirements” to more accurately reflect the fact that some examples provided in this section do not meet the definition of a “device.”

Guidance: Policy for Device Software Functions and Mobile Medical Applications – Guidance for Industry and Food and Drug Administration Staff

Overview
This guidance supersedes the February 9, 2015, “Mobile Medical Applications” guidance. While FDA broadened the scope of the guidance to include device software that includes mobile applications, FDA reiterated that it intends to apply regulatory oversight to only those software functions that:

  • Are an extension of one or more medical devices by connecting to such device(s) for purposes of controlling the device(s) or analyzing medical device data
  • Transform the mobile platform into a regulated medical device by using attachments, display screens or sensors, or by including functionalities similar to those of currently regulated medical devices
  • Become a regulated medical device by performing patient-specific analysis and providing patient-specific diagnosis or treatment recommendations.

FDA intends to continue exercising enforcement discretion (i.e., based on FDA’s current understanding of risks, it does not intend to enforce compliance with applicable device requirements) over the following software functions:

  • Helping patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions
  • Automating simple tasks for healthcare providers (HCPs)
  • Providing or facilitating supplemental care by coaching to help patients manage their health in their daily environment
  • Facilitating access to information related to the patients’ health conditions or treatments (beyond providing an electronic “copy” of a medical reference)
  • Allowing patients to communicate with their HCPs by supplementing or augmenting data or information by capturing a image for patients to send to their HCPs about potential medical conditions
  • Performing simple calculations otherwise normally used in a clinical practice.

FDA also moved a number of examples from Appendix B (examples of mobile apps for which FDA intends to exercise enforcement discretion) or Section V.B (examples of mobile apps for which FDA intends to exercise enforcement discretion, such as functions that enable patients or HCPs to interact with electronic health record (EHR) systems or those intended to transfer, store, convert, format and display medical device data in its original form) to Appendix A (examples of mobile apps that are NOT medical devices) because they no longer meet the definition of a “device.”

Guidance: Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices – Guidance for Industry and Food and Drug Administration Staff

Overview
Since the Cures Act excludes software that is intended for “transferring, storing, covering formats, or displaying clinical laboratory test or other device data and results unless such function is intended to interpret or analyze clinical laboratory test or other device data, results, and findings” (emphasis added), Medical Device Data Systems (MDDS), medical image storage devices and medical image communications devices no longer meet the definition of a “device.”

The guidance defines “Non-Device-MDDS” as software functions that are solely intended to transfer, store or convert formats and display medical device data or results. However, software functions that “analyze or interpret” medical device data and results, such as medical images, waveforms, signals or other clinical information, remain devices. Additionally, software functions intended to generate alarms or alerts or prioritize patient-related information on multi-patient displays are not excluded from the definition of a “device,” because they involve analysis or interpretation of laboratory tests or other device data and results.

The guidance also defines “Device-MDDS” as hardware functions that are solely intended to transfer, store or convert formats and display medical device data or results. Hardware that is intended to transfer, store, convert formats and display medical device data and results remains a device unless it is used solely for transfer, storage or conversion of formats and to display medical device data or results.

FDA intends to provide recommendations on Non-Device-MDDS and Device-MDDS functions with respect to how they affect the safety and effectiveness of device function(s) in multiple function device products in a separate guidance.

Guidance: Off-the-Shelf Software Uses in Medical Devices

Overview
In the revised guidance, which updates the September 1999 guidance, FDA removed the section on “Exemption of Laboratory Information Management Systems,” for Laboratory Information Systems and Laboratory Information Management Systems functions, which includes calculator/data processing modules for clinical use under 21 CFR section 862.2100, intended for administrative support. FDA made this change because FDA no longer regulates software that simply transfers, stores, converts formats or displays clinical laboratory test data and results as a “device.”

Guidance: Clinical Decision Support Software – Draft Guidance for Industry and Food and Drug Administration Staff

Overview
FDA clarified that the term “clinical decision support” (CDS) is used broadly. CDS provides HCPs and patients with information, “intelligently filtered or presented at appropriate times” to enhance healthcare. Under section 520(o)(1)(E) of the FDCA, software that meets all of the following criteria are excluded from the definition of a “device,” (further discussed here):

  • Not intended to acquire, process or analyze a medical image or a signal from an in vitro diagnostic device or pattern or signal from a signal acquisition system
  • Intended for the purpose of displaying, analyzing or printing medical information about a patient or other medical information (e.g., peer-reviewed clinical studies and clinical practice guidelines)
  • Intended for the purpose of supporting or providing recommendations to an HCP about prevention, diagnosis or treatment of a disease or condition
  • Intended for the purpose of enabling an HCP to independently review the basis for such recommendations that the software presents so that it is not the intent that a HCP rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient.

The most significant element is whether the HCP can independently review the basis for information or recommendations the software presents, so that the HCP is not required to rely primarily on any of such recommendations to make a decision regarding a patient.

In the previous version of the draft guidance, FDA stated that it also intended to exercise enforcement discretion over products intended for patients or caregivers if the software generally paralleled CDS for HCPs and met all four criteria above. The revised guidance removes the concept of “patient decision support” or “PDS” software. FDA now considers all CDS software that is intended for a patient or caregiver, regardless of whether the user can independently review the basis for information or recommendations presented by the software, to be “Device CDS,” although some Device CDS software intended for patient or caregiver use remains subject to enforcement discretion. For example, software that provides information to a patient about the use of a prescription drug that is consistent with both FDA-approved labeling and the patient’s prescription, such as software that reminds a patient how or when to take a prescribed drug, remains under enforcement discretion.

If the software is intended for an HCP and the HCP can independently review the basis for information or recommendations, the software is “Non-Device CDS.” The revised guidance clarifies that “Non-Device CDS” includes software functions that meet all criteria in the basic framework and only includes software intended for HCPs.

For Device CDS, FDA has adopted the International Medical Device Regulators Forum (IMDRF) risk-based framework for categorizing products, which evaluates (1) the significance of the information provided by the product to a healthcare decision (to treat or diagnose, to drive clinical management or to inform clinical management) against (2) the state of the healthcare condition (critical, serious, non-serious). See IMDRF “‘Software as a Medical Device’: Possible Framework for Risk Categorization and Corresponding Considerations.” Based on this, FDA has established a summary of its current regulatory policy and added examples for each of the following categories:

  • Non-Device CDS
  • Device CDS functions for which FDA intends to exercise enforcement discretion
  • Device CDS functions on which FDA intends to focus regulatory oversight
  • Non-Device CDS functions on which FDA intends to focus regulatory oversight (e.g., software that manipulates or analyzes images to create models intended to be used in planning surgical treatments).

 

Intended User Is HCP

Intended User Is Patient or Caregiver

 

IMDRF Risk Categorization

Can User Independently Review Basis of Recommendation?

 

Regulatory Status

 

 

 

Inform x Critical

 

Yes

Non-Device CDS

Device CDS

Oversight Focus

 

No

Device CDS

Oversight Focus

Device CDS

Oversight Focus

 

 

Inform x Serious

 

Yes

 

Non-Device CDS

Device CDS

Oversight Focus

 

No

Device CDS

Oversight Focus

Device CDS

Oversight Focus

 

 

Inform x Non-Serious

 

Yes

 

Non-Device CDS

Device CDS – Enforcement Discretion

 

No

Device CDS – Enforcement Discretion

Device CDS

Oversight Focus

The guidance is open to public comment until December 26, 2019. FDA intends to make conforming edits to the Policy for Device Software Functions and Mobile Medical Applications – Guidance for Industry and Food and Drug Administration Staff after finalizing this guidance.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDermott Will & Emery | Attorney Advertising

Written by:

McDermott Will & Emery
Contact
more
less

McDermott Will & Emery on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.